Journal
BRITISH JOURNAL OF PHARMACOLOGY
Volume 152, Issue 8, Pages 1155-1171Publisher
WILEY
DOI: 10.1038/sj.bjp.0707354
Keywords
human African trypanosomiasis; sleeping sickness; melarsoprol; suramin; pentamidine; eflornithine; nifurtimox; furamidine; pafuramidine; neglected disease
Categories
Ask authors/readers for more resources
This review discusses the challenges of chemotherapy for human African trypanosomiasis (HAT). The few drugs registered for use against the disease are unsatisfactory for a number of reasons. HAT has two stages. In stage 1 the parasites proliferate in the haemolymphatic system. In stage 2 they invade the central nervous system and brain provoking progressive neurological dysfunction leading to symptoms that include the disrupted sleep wake patterns that give HAT its more common name of sleeping sickness. Targeting drugs to the central nervous system offers many challenges. However, it is the cost of drug development for diseases like HAT, that afflict exclusively people of the world's poorest populations, that has been the principal barrier to new drug development and has led to them becoming neglected. Here we review drugs currently registered for HAT, and also discuss the few compounds progressing through clinical trials. Finally we report on new initiatives that might allow progress to be made in developing new and satisfactory drugs for this terrible disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available